Unlock Our Metabolic Capabilities
We offer a comprehensive metabolic disease drug discovery service portfolio. Explore our comprehensive metabolic disease drug discovery service portfolio. Let us guide your program from lead candidate, to mechanism-of-action studies, to preparation for IND submission. Our in vivo pharmacology models for metabolic and cardiovascular disease include:
- Nonalcoholic Steatohepatitis (NASH)
- Diet-induced Obesity
- Type 1 Diabetes
- Type 2 Diabetes
- Fatty Liver Disease
- Dyslipidemia and Atherosclerosis
- Vascular Inflammation
Combining our well-characterized in vivo models and broad suite of translational biomarkers, gives our partners the flexibility they need to demonstrate therapeutic efficacy of their compounds and advance their research program.
What can we accomplish together? Let’s find out.